Loading...
DOCUMENTS
20
NOTICES
33
MOTS CLES
Effectiveness
Drug
Screening
Inhibitor
18 FDG-PET/CT
Colorectal cancer Colibactin and lipids
RISK
Eradication
Patients experience
Anti-TNF agents
IL23
Anti-TNF
Colon
COLON-CANCER
Crohn’s disease
Fecal microbiota
Epigenetics
Colon cancer
Disease progression
Inclusion
MALT
MORTALITY
Therapeutics
Methylation
Tailored therapy
Maintenance therapy
Gènes
Heart disease risk factors
Neoadjuvant chemotherapy
Bactéries
Disability
IL12
Surgery
Inflammatory Bowel Diseases
Cost effectiveness
Resistance
Méthylation
Helicobacter pylori
MARKER
Parvimonas micra
Vedolizumab
Biomarker
DNA methylation
Ulcerative colitis
Résistance
Tuberculosis
Genes
Immune cells
Rituximab plus chlorambucil
Cell adhesion
Microbiote
Original Article Clinical
Crohn's disease
HIV
Intestinal crypts
Contraindication
CARCINOGENESIS
Clinical guidelines
Alkylating agents
IBD
DNA METHYLATION
Thérapie ciblée
Inflammatory bowel diseases
Rituximab
Bacteria
Gene methylation
Immunosuppressant
MICROBIOTA
Ustekinumab
Cancer
Survival
Eligibility
Acceptability
Epigénétiques
Small molecules
Endoscopic treatment
T1118 translocation
Patient-reported outcome
Biologics
Safety
Primary sclerosing cholangitis
Monitoring
Dysbiosis
Over 80s
Colonic epithelial primary cells
Gene expression
Algorithm
Clinical trial
Venous thromboembolism
Dysbiose
Upper gastrointestinal tract
Microbiota
Colectomy
Stricture
Inflammatory bowel disease
Colorectal cancer
Kidney diseases
PCR
Disease Progression
Consensus
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|
Derniers dépôts
-
Iradj Sobhani, Emma Bergsten, Cecile Charpy, Mathias Chamaillard, Denis Mestivier. Virulent Bacteria as Inflammatory and Immune Co-Factor in Colon Carcinogenesis: Evidence From Two Monozygotic Patients and Validation in CRC Patient and Healthy Cohorts. Frontiers in Cellular and Infection Microbiology, 2021, 11, pp.749750. ⟨10.3389/fcimb.2021.749750⟩. ⟨hal-04543208⟩
-
Lucas Guillo, Guillaume Savoye, Aurélien Amiot, Cyrielle Gilletta, Maria Nachury, et al.. Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID. Clinical and translational gastroenterology, 2023, 14 (12), pp.e00607. ⟨10.14309/ctg.0000000000000607⟩. ⟨hal-04206330⟩
-
Florence Canouï-Poitrine, Astrid Lièvre, Florent Dayde, Daniel Lopez-Trabada-Ataz, Isabelle Baumgaertner, et al.. Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. Oncologist, 2019, 24 (12), pp.e1351-e1359. ⟨10.1634/theoncologist.2019-0166⟩. ⟨hal-04126614⟩
-
Maria Nachury, Yoram Bouhnik, Mélanie Serrero, Jerome Filippi, Xavier Roblin, et al.. Patients’ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. Digestive and Liver Disease, 2021, 53 (4), pp.434-441. ⟨10.1016/j.dld.2020.10.020⟩. ⟨hal-03038260⟩
-
Julien Tap, Aurélien Amiot, Véronique Jarrousse, Sandra Guilmeau, Jeanne Tran Vannhieu, et al.. Early Phenotypical Changes Induced By Transfer Of Human Fecal Microbiota from Colorectal Cancer Patients To Germ-Free Mice. International Journal of Cancer and Oncology, 2017, 4 (1), pp. 1-11. ⟨10.15436/2377-0902.16.1128⟩. ⟨hal-03825702⟩
-
Nicolas Petitdidier, Laurent Beaugerie, Franck Carbonnel, Anne Bourrier, Xavier Treton, et al.. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, pp.609 - 618. ⟨10.1016/j.clinre.2019.11.008⟩. ⟨hal-03492351⟩
-
Nicolas Petitdidier, Jenny Tannoury, Nicola De’angelis, Charlotte Gagniere, Anne Hulin, et al.. Patients’ perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Digestive and Liver Disease, 2019, 51, pp.1652 - 1660. ⟨10.1016/j.dld.2019.08.020⟩. ⟨hal-03489097⟩